: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook
The ticker is no longer active for trading. TransEnterix, the company originally associated with that symbol, rebranded as Asensus Surgical and changed its ticker to ASXC in March 2021. Subsequently, Asensus Surgical was acquired by KARL STORZ and its stock was officially delisted in August 2024. Stock Status and Delisting trxc stock buy or sell
AI responses may include mistakes. For financial advice, consult a professional. Learn more : Leading up to its acquisition, the company
Since the company is now , it is not possible to buy or sell shares on public markets. Subsequently, Asensus Surgical was acquired by KARL STORZ
: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout.